What is Xcovery?
Xcovery operates at the intersection of advanced molecular science and patient-centric oncology care. The firm is dedicated to the discovery and development of next-generation cancer therapies designed to improve efficacy while simultaneously reducing systemic toxicity. By prioritizing the transition of life-changing agents from laboratory research to clinical application, Xcovery addresses critical unmet medical needs. Its market position is defined by a commitment to therapeutic precision, aiming to provide patients with more tolerable treatment options that enhance both longevity and quality of life. The company's operational model integrates deep scientific expertise with a compassionate approach to drug development, positioning it as a significant player in the global biopharmaceutical landscape.
How much funding has Xcovery raised?
Xcovery has raised a total of $48.9M across 8 funding rounds:
Series A
$2.4M
Series B
$6M
Debt
$2.1M
Multiple Rounds
$38.1M
Debt
$350K
Series A (2011): $2.4M, investors not publicly disclosed
Series B (2012): $6M, investors not publicly disclosed
Debt (2013): $2.1M, investors not publicly disclosed
Series C (2014): $2.4M, investors not publicly disclosed
Series D (2014): $15M backed by EMS S/A and Brace Pharma
Debt (2014): $675K, investors not publicly disclosed
Private Equity (2014): $20M led by Betta Pharmaceuticals
Debt (2020): $350K supported by PPP
Key Investors in Xcovery
Betta Pharmaceuticals
A leading Chinese pharmaceutical firm specializing in the development and commercialization of innovative oncology products, including targeted therapies for non-small cell lung cancer.
EMS S/A
A prominent Brazilian pharmaceutical company with a long-standing history in the distribution and development of healthcare solutions across the region.
Brace Pharma
An investment firm focused on supporting life-changing medicines and innovative therapies for diseases with significant unmet medical needs.
What's next for Xcovery?
With the recent infusion of capital, Xcovery is well-positioned to accelerate its late-stage clinical programs and expand its research capabilities. The strategic focus will likely shift toward navigating regulatory milestones and scaling manufacturing processes to support the commercialization of its lead candidates. As the company continues to leverage its partnerships with global pharmaceutical entities, the emphasis remains on achieving proof-of-concept for its diverse portfolio of small-molecule and biologic therapies. Future growth will be driven by the successful execution of its clinical development roadmap, ensuring that innovative oncology solutions reach the market with the speed and safety required to transform patient outcomes in the competitive cancer treatment sector.
See full Xcovery company page
